5-Amino-1MQ for fat loss: promising mouse data, zero human trials

What did @brian_dadbod2.0 actually say?

The creator describes 5-Amino-1MQ as a compound that targets fat storage and metabolism, helps people "lose body fat while retaining muscle mass," and works by inhibiting an enzyme called NNMT (nicotinamide N-methyltransferase). He says blocking NNMT raises NAD+ levels, improves cellular energy efficiency, and activates SIRT1, which he calls the "longevity gene." The overall framing is that this is a promising, science-backed tool for body recomposition.

To his credit, the mechanism he describes is real. This is not someone making up pseudoscience. The NNMT inhibition pathway is genuinely being studied. But the gap between "lab research exists" and "this compound will change your body" is wider than this video acknowledges, and viewers deserve to know that.

Does the science back this up?

Partially, yes, but almost entirely in animal models. The human data is thin to nonexistent for this specific compound.

The NNMT enzyme is a legitimate target. Studies have shown that NNMT plays a role in adipogenesis and energy expenditure. Eckert et al. (2023, Cell Metabolism) demonstrated that NNMT inhibition in obese mice reduced fat mass and improved metabolic markers. Hong et al. (2015, Nature Communications) showed that NNMT knockdown in adipose tissue protected mice from diet-induced obesity. These are real findings in peer-reviewed journals.

The SIRT1 connection also has some basis. NAD+ is a known co-substrate for sirtuins including SIRT1, and boosting cellular NAD+ does appear to activate sirtuin pathways. Guarente (2013, Cell) established much of the foundational sirtuin biology. But calling SIRT1 simply the "longevity gene" flattens a complicated, context-dependent biology into a marketing phrase.

The problem: no published human clinical trials on 5-Amino-1MQ for fat loss or muscle retention exist in the peer-reviewed literature as of mid-2025. What exists is rodent data and mechanistic cell studies. That matters enormously when a video implies it works for human body recomposition.

What did they get wrong (or right)?

He got the mechanism mostly right. The enzyme name, the NAD+ connection, and the SIRT1 pathway are accurately described in broad strokes. Give credit where it is due.

What he got wrong, or at least oversimplified, is the leap from mechanism to outcome. Saying 5-Amino-1MQ is "becoming more popular for its ability to help somebody lose body fat while retaining muscle mass" implies clinical efficacy. Popularity is not evidence. Many compounds become popular before human data exists, and some wash out entirely when trials run.

The phrase "designed to enhance metabolism" also deserves scrutiny. 5-Amino-1MQ is a research compound, not an approved therapeutic. Describing it as something purposefully designed for human metabolic enhancement misrepresents its current regulatory and research status. It is an investigational NNMT inhibitor, primarily studied in preclinical settings.

• Accurate: NNMT inhibition mechanism and its link to fat metabolism
• Accurate: NAD+ elevation as a downstream effect of NNMT inhibition
• Mostly accurate: SIRT1 activation through NAD+ signaling
• Misleading: Implied clinical efficacy for human fat loss and muscle retention
• Misleading: Framing the compound as something with established human outcomes

What should you actually know?

The honest summary is that 5-Amino-1MQ has a mechanistically interesting basis, but human evidence for fat loss or muscle retention does not yet exist in the published literature. That does not mean the compound has no future. It means we are early.

NNMT inhibition is a serious research area. A 2021 paper by Neelakantan et al. in the Journal of Medicinal Chemistry specifically studied small-molecule NNMT inhibitors including structural analogs relevant to this compound class, and found promising metabolic effects in cell and mouse models. But mouse metabolism and human metabolism are not the same system, and the history of metabolic drugs is full of compounds that worked in rodents and failed or caused harm in humans.

If you are considering 5-Amino-1MQ, the conversation needs to happen with a licensed clinician who can assess your individual health status, review the limited available literature with you, and monitor for any adverse effects. This is not a supplement you find at a vitamin store. It is an unregulated research compound, and the absence of clinical trial data means the safety profile in humans is not fully established.

The video is not reckless, but it is incomplete. Incomplete information about compounds with real physiological effects is its own kind of risk.